Family Medicine Doctors in Sheridan, MT Accepting Medicare
1 Family Medicine doctors found. Showing 1 - 1
 Dr. Roman Michael Hendrickson Sr., MD Family Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 210 E Crofoot St, Sheridan, MT 59749 Phone: 406-842-5056 Fax: 406-842-5057 |
News Archive
Interim results from Phase I clinical trial of PLX-PAD for treatment of CLI
Pluristem Therapeutics Inc. today announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia, the end-stage of peripheral artery disease. The interim data demonstrated that PLX-PAD is safe, well tolerated and effective.
Researchers discover mechanism that control normal lung function in patients with BHD syndrome
Researchers at Penn Medicine have discovered that the tumor suppressor gene folliculin (FLCN) is essential to normal lung function in patients with the rare disease Birt-Hogg-Dube (BHD) syndrome, a genetic disorder that affects the lungs, skin and kidneys. Folliculin's absence or mutated state has a cascading effect that leads to deteriorated lung integrity and an impairment of lung function, as reported in their findings in the current issue of Cell Reports.
Scientists identify proteasome phosphatase that appears to regulate removal of damaged proteins
A study by scientists at the University of California, San Diego and UC Irvine has identified an enzyme called a proteasome phosphatase that appears to regulate removal of damaged proteins from a cell. The understanding of how this process works could have important implications for numerous diseases, including cancer and Parkinson's disease.
Occupational exposure to substances is a major risk factor for neurodermatitis
A child who can't stop scratching himself may well be suffering from atopic dermatitis, also known as neurodermatitis. Extreme irritability of the skin with a concomitant urge to scratch is typical of the disorder. The condition often appears during the first year of life and is on the increase in industrialized countries.
Gilead presents Phase IIa data for HCV therapy at The Liver Meeting 2010
Gilead Sciences, Inc. today announced data from a Phase IIa study showing that its investigational compounds GS 9190 and GS 9256, used in conjunction with current standard of care therapies, produced substantial suppression of the hepatitis C virus (HCV) within 28 days of treatment.
› Verified 9 days ago